MA44021B1 - Composés antitumoraux - Google Patents

Composés antitumoraux

Info

Publication number
MA44021B1
MA44021B1 MA44021A MA44021A MA44021B1 MA 44021 B1 MA44021 B1 MA 44021B1 MA 44021 A MA44021 A MA 44021A MA 44021 A MA44021 A MA 44021A MA 44021 B1 MA44021 B1 MA 44021B1
Authority
MA
Morocco
Prior art keywords
antitumor compounds
antitumor
compounds
cancer
compound
Prior art date
Application number
MA44021A
Other languages
English (en)
Other versions
MA44021A (fr
Inventor
Marchante María Del Carmen Cuevas
Solloso Andrés Francesch
Barrasa Valentín Martínez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MA44021A publication Critical patent/MA44021A/fr
Publication of MA44021B1 publication Critical patent/MA44021B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

La présente invention concerne un composé de formule générale i, dans laquelle r1 à r4 ont diverses significations, et est destiné à être utilisé dans le traitement du cancer.
MA44021A 2017-04-27 2018-04-27 Composés antitumoraux MA44021B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26

Publications (2)

Publication Number Publication Date
MA44021A MA44021A (fr) 2019-05-15
MA44021B1 true MA44021B1 (fr) 2019-08-30

Family

ID=62063080

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44021A MA44021B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux
MA44020A MA44020B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA44020A MA44020B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Country Status (37)

Country Link
US (4) US11332480B2 (fr)
EP (5) EP3615544B9 (fr)
JP (5) JP6501946B2 (fr)
KR (3) KR102510975B1 (fr)
CN (4) CN117865987A (fr)
AU (4) AU2018260314C1 (fr)
BR (1) BR112019022282A2 (fr)
CA (1) CA3061518A1 (fr)
CL (1) CL2019003057A1 (fr)
CO (1) CO2019011967A2 (fr)
CY (3) CY1121885T1 (fr)
DK (5) DK4101855T3 (fr)
EC (1) ECSP19083967A (fr)
ES (5) ES2944344T3 (fr)
FI (3) FI4101855T3 (fr)
HK (2) HK1255941B (fr)
HR (5) HRP20230455T1 (fr)
HU (5) HUE062157T2 (fr)
IL (3) IL295044B2 (fr)
JO (1) JOP20190254A1 (fr)
LT (5) LT3615544T (fr)
MA (2) MA44021B1 (fr)
MD (5) MD3395821T2 (fr)
ME (2) ME03466B (fr)
MX (3) MX2021016054A (fr)
MY (1) MY198004A (fr)
PH (1) PH12019550224A1 (fr)
PL (5) PL4101855T3 (fr)
PT (2) PT3395821T (fr)
RS (5) RS64174B1 (fr)
SG (2) SG11201909841RA (fr)
SI (5) SI3615544T1 (fr)
TN (2) TN2019000210A1 (fr)
TW (3) TWI742273B (fr)
UY (1) UY37706A (fr)
WO (1) WO2018197663A1 (fr)
ZA (1) ZA201907119B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN115151259A (zh) * 2019-11-21 2022-10-04 法马马有限公司 用鲁比卡丁制剂治疗小细胞肺癌的方法
EP4138923A1 (fr) 2020-04-21 2023-03-01 Pharma Mar, S.A. Conjugués médicament-anticorps
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
EP4340841A1 (fr) 2021-05-19 2024-03-27 Pharma Mar S.A. Schémas posologiques pour l'écubectédine

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
EP0048149B1 (fr) 1980-09-12 1983-11-30 University of Illinois Foundation Antibiotiques, dérivés de ceux-ci, procédé de leur extraction et compositions contenant ceux-ci
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
DE3584370D1 (de) 1984-12-28 1991-11-14 Conpharm Ab Verwendung von podophyllotoxin und dessen derivaten.
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
ATE74761T1 (de) 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
AU589282B2 (en) 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
ES2054011T3 (es) 1988-09-05 1994-08-01 Sankyo Co Un proceso para la preparacion de un compuesto, "leualacina".
WO1990005731A1 (fr) 1988-11-24 1990-05-31 University Of Queensland Macromolecules cytotoxiques
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (fr) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
WO1994004541A2 (fr) 1992-08-12 1994-03-03 The Upjohn Company Inhibiteurs de proteine kinase et composes apparentes combines avec du taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (fr) 1996-03-29 1999-06-02 Rohm And Haas Company Sphinogolipides et procédé pour ceux-ci
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DE69723728T2 (de) 1996-10-24 2004-06-03 The Board Of Trustees For The University Of Illinois, Urbana Totalsynthese des amino hip analogen von didemnin a
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
DE69840497D1 (de) 1997-05-07 2009-03-12 William J Crumb Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
IL138856A0 (en) 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
KR100603220B1 (ko) 1998-05-05 2006-07-20 파르마 마르, 에스.에이. 고착성 해양동물의 배양방법
CN100548988C (zh) 1998-05-11 2009-10-14 法马马有限公司 海鞘素743的代谢物
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ATE363910T1 (de) 1999-11-15 2007-06-15 Pharma Mar Sa Behandlung von krebserkrankungen durch aplidin
EP1254140A4 (fr) 2000-01-19 2003-03-12 Univ Columbia Composes de la serie saframycine-ecteinascidine, utilisations et synthese
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
WO2001076616A1 (fr) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Analogues de tamandarine et de didemnine et methodes de fabrication et d'utilisation correspondantes
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
WO2001077115A1 (fr) 2000-04-12 2001-10-18 Pharma Mar, S.A. Derives antitumoraux d'ecteinascidines
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
DE60131076T2 (de) 2000-06-06 2008-07-31 Pharma Mar, S.A., Tres Cantos Antitumorale verbindungen
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
KR100886161B1 (ko) 2000-07-11 2009-02-27 파르마 마르, 에스.에이. 항암제로서의 배리올린 유도체
US6635054B2 (en) 2000-07-13 2003-10-21 Transurgical, Inc. Thermal treatment methods and apparatus with focused energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
AU9402401A (en) 2000-10-12 2002-04-22 Pharma Mar Sa Treatment of cancers
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
CN1568192A (zh) 2000-10-31 2005-01-19 法马马有限公司 KahalalideF制剂
CA2428160C (fr) 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions contenant de l'ecteinascidine 743 pour traitement antitumoral
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
CA2435418A1 (fr) 2001-01-24 2002-08-01 Mestex Ag Utilisation de substances neurotoxiques pour la production d'un agent servant a traiter les douleurs articulaires
EP1353667A1 (fr) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
EP1360337A1 (fr) 2001-02-09 2003-11-12 The Regents Of The University Of California Composes de la famille de l'ecteinascidine: compositions et procedes
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003033012A1 (fr) 2001-10-19 2003-04-24 Pharma Mar, S.A. Composes a base de kahalalide utilisables en therapie anticancereuse
CA2462502A1 (fr) 2001-10-19 2003-05-15 Pharma Mar, S.A. Utilisation amelioree de compose anti-tumoral dans le traitement des cancers
PT1435991E (pt) 2001-10-19 2009-01-16 Pharma Mar Sa Utilização de aplidina para o tratamento de cancro pancreático
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
EP2357006B1 (fr) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Conjugués de médicaments et leur utilisation pour traiter le cancer, maladie auto-immune ou maladie infectieuse
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
EP1551315A2 (fr) * 2002-10-04 2005-07-13 St. Jude Medical ATG, Inc. Connecteurs externes auto-dilatables permettant de creer des anastomoses sur des vaisseaux de faible diametre et procedes d'utilisation
AU2003277287A1 (en) * 2002-10-08 2004-05-04 Warsaw Orthopedic, Inc. Insertion device and techniques for orthopaedic implants
EP1572726B1 (fr) 2002-10-18 2010-12-08 Pharma Mar, S.A.U. Composes 4-methylhexanoic kahalalide f
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
KR20060002778A (ko) 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
AU2004218883B2 (en) 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
WO2004084812A2 (fr) 2003-03-21 2004-10-07 Joullie Madeleine M Analogues de « tamandarin », fragments associes et leurs methodes d'elaboration et d'utilisation
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
AU2004263287B2 (en) 2003-07-25 2009-02-12 Novartis Ag Substituted lactams and their use as anti-cancer agents
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
DE602004018811D1 (de) 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005049030A1 (fr) 2003-11-14 2005-06-02 Pharma Mar, S.A. Therapie anticancer utilisant une combinaison de et-743 et de paclitaxel
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (fr) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
JP2008505862A (ja) 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
CN101068596A (zh) 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
CN101119750B (zh) 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
WO2006066183A2 (fr) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
AU2006243407A1 (en) 2005-05-03 2006-11-09 Pharma Mar, S.A. Antitumoral tetrahydro-pyrimidines
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
RU2008107974A (ru) 2005-08-02 2009-09-10 Фарма Мар, С.А. (Es) Гены, участвующие в биосинтезе тиокоралина и его гетерологичном продуцировании
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
EP1962843B1 (fr) 2005-11-25 2011-02-23 Pharma Mar S.A., Sociedad Unipersonal Utilisation d'inhibiteurs du parp-1
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
ES2575518T3 (es) 2006-02-28 2016-06-29 Pharma Mar S.A. Tratamiento mejorado de mieloma múltiple
AU2007249281A1 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
NZ573706A (en) 2006-06-16 2011-09-30 Pharma Mar Sa Antitumoral dihydropyran-2-one compounds
KR20100099128A (ko) 2007-10-19 2010-09-10 파르마 마르 에스.에이. 개선된 항암치료
US20100267732A1 (en) 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
AU2008313627A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
ES2406107T3 (es) 2007-12-14 2013-06-05 Pharma Mar S.A. Compuestos antitumorales
DK2231590T3 (da) 2007-12-20 2012-07-09 Pharma Mar Sa Antitumorforbindelser
US20100323021A1 (en) 2008-01-30 2010-12-23 Pharma Mar, S.A. Antitumoral treatments
RU2010140890A (ru) 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные способы противоопухолевого лечения
CN101965191A (zh) 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
AU2009246130A1 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with PM00 104 and another antitumor agent
WO2009138509A1 (fr) 2008-05-16 2009-11-19 Pharma Mar, S.A. Traitements du myélome multiple
WO2009143317A1 (fr) 2008-05-23 2009-11-26 Wyeth Composés de triazine formant des inhibiteurs de pi3-kinase et mtor
RU2011103778A (ru) 2008-07-03 2012-08-10 Фарма Мар, С.А. (Es) Противоопухолевые макролиды
JP6067222B2 (ja) 2008-07-15 2017-01-25 ジェネンテック， インコーポレイテッド アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途
CA2730663A1 (fr) 2008-07-17 2010-01-21 Pharma Mar, S.A. Composes anticancereux
EP2373678A1 (fr) 2008-12-19 2011-10-12 Pharma Mar S.A. Composés anticancéreux
WO2010149688A2 (fr) 2009-06-24 2010-12-29 Pharma Mar, S.A. Composés anticancéreux
HUE028751T2 (en) 2010-04-27 2017-01-30 Pharma Mar Sa Unsaturated, anticancer steroid lactones at position 8 (7)
JP6037337B2 (ja) 2010-05-25 2016-12-07 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍｒｓ，Ｓ．Ａ． エクチナサイジン化合物の製造のための合成方法
BR122017028570B1 (pt) 2010-11-12 2022-03-03 Pharma Mar, S.A Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit
DE102012211024A1 (de) 2012-06-27 2014-01-02 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
AU2017296338A1 (en) 2016-07-14 2019-01-03 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
US11713325B2 (en) 2023-08-01
LT4101855T (lt) 2023-08-25
TW202202509A (zh) 2022-01-16
JP7422812B2 (ja) 2024-01-26
LT3395821T (lt) 2019-08-12
MA44020A (fr) 2018-10-31
EP3395821A1 (fr) 2018-10-31
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
TWI742273B (zh) 2021-10-11
HRP20191443T1 (hr) 2019-11-15
DK3395821T3 (da) 2019-08-19
RS64686B1 (sr) 2023-11-30
KR102491180B1 (ko) 2023-01-20
SI3395820T1 (sl) 2019-09-30
KR20220109495A (ko) 2022-08-04
MA44021A (fr) 2019-05-15
RS59173B1 (sr) 2019-10-31
PT3395820T (pt) 2019-08-07
TW202344509A (zh) 2023-11-16
EP3615544A1 (fr) 2020-03-04
IL295044B1 (en) 2023-07-01
IL270153A (fr) 2019-12-31
CN117865987A (zh) 2024-04-12
JP6501947B2 (ja) 2019-04-17
MX2021016058A (es) 2022-02-03
AU2022200250C1 (en) 2022-06-23
MY198004A (en) 2023-07-25
DK4101855T3 (da) 2023-11-06
HRP20230433T1 (hr) 2023-07-07
CO2019011967A2 (es) 2020-02-18
JP6501946B2 (ja) 2019-04-17
FI3615544T3 (fi) 2023-05-23
SI3615544T1 (sl) 2023-07-31
KR20210126791A (ko) 2021-10-20
IL289963B2 (en) 2023-10-01
MD3615544T2 (ro) 2023-08-31
CY1121884T1 (el) 2020-10-14
TN2019000211A1 (en) 2021-01-07
KR102510975B1 (ko) 2023-03-16
HK1255941B (zh) 2020-04-29
PH12019550224A1 (en) 2020-10-12
ECSP19083967A (es) 2019-12-27
IL270153B1 (en) 2023-06-01
HRP20230455T1 (hr) 2023-07-21
EP3615544B9 (fr) 2024-01-03
AU2018260314B2 (en) 2021-12-09
HUE062157T2 (hu) 2023-10-28
EP3395820B1 (fr) 2019-05-15
US20220242883A1 (en) 2022-08-04
JP2023052597A (ja) 2023-04-11
RS64200B1 (sr) 2023-06-30
US20180312529A1 (en) 2018-11-01
HUE063736T2 (hu) 2024-01-28
AU2022200249B1 (en) 2022-02-10
SI3395821T1 (sl) 2019-09-30
DK3395820T3 (da) 2019-08-12
CA3061518A1 (fr) 2018-11-01
CN114736219A (zh) 2022-07-12
ES2740073T3 (es) 2020-02-05
ME03466B (fr) 2020-01-20
JP2022130682A (ja) 2022-09-06
CN110621678A (zh) 2019-12-27
US20210246146A1 (en) 2021-08-12
AU2022201657A1 (en) 2022-03-31
HUE046109T2 (hu) 2020-02-28
EP3395820A1 (fr) 2018-10-31
WO2018197663A1 (fr) 2018-11-01
ES2944579T3 (es) 2023-06-22
IL289963A (en) 2022-03-01
LT3395820T (lt) 2019-08-12
AU2022200250B1 (en) 2022-02-10
IL289963B1 (en) 2023-06-01
SI4101855T1 (sl) 2024-03-29
CY1126061T1 (el) 2023-11-15
JOP20190254A1 (ar) 2019-10-27
ZA201907119B (en) 2021-07-28
AU2018260314C1 (en) 2022-04-21
PL3615544T3 (pl) 2023-07-17
BR112019022282A2 (pt) 2020-05-19
PL4047002T3 (pl) 2023-07-24
EP4047002B1 (fr) 2023-03-08
HUE045641T2 (hu) 2020-01-28
US20210070775A1 (en) 2021-03-11
UY37706A (es) 2018-11-30
US10538535B2 (en) 2020-01-21
AU2018260314A1 (en) 2019-10-31
JP2018188431A (ja) 2018-11-29
JP7186723B2 (ja) 2022-12-09
MX2019012812A (es) 2020-01-14
LT3615544T (lt) 2023-05-10
FI4101855T3 (fi) 2023-09-22
EP4101855A1 (fr) 2022-12-14
TWI807411B (zh) 2023-07-01
PL3395821T3 (pl) 2019-10-31
CL2019003057A1 (es) 2020-02-21
IL270153B2 (en) 2023-10-01
PT3395821T (pt) 2019-08-27
KR102492283B1 (ko) 2023-01-27
HRP20191442T1 (hr) 2019-11-15
IL295044A (en) 2022-09-01
ES2960063T3 (es) 2024-02-29
EP4101855B1 (fr) 2023-08-02
IL295044B2 (en) 2023-11-01
EP3395821B1 (fr) 2019-05-15
DK4047002T3 (da) 2023-05-01
FI4047002T3 (fi) 2023-05-22
KR20200012846A (ko) 2020-02-05
EP4101855B9 (fr) 2024-01-03
ES2741901T3 (es) 2020-02-12
EP3615544B1 (fr) 2023-03-22
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
MX2021016054A (es) 2022-06-01
RS59174B1 (sr) 2019-10-31
TW201906850A (zh) 2019-02-16
US11332480B2 (en) 2022-05-17
ME03467B (fr) 2020-01-20
MD4047002T2 (ro) 2023-08-31
DK3615544T3 (da) 2023-05-30
JP2018188432A (ja) 2018-11-29
SG11201909841RA (en) 2019-11-28
HUE062032T2 (hu) 2023-09-28
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
SG10201913300YA (en) 2020-03-30
EP4047002A1 (fr) 2022-08-24
RS64174B1 (sr) 2023-05-31
JP2020517709A (ja) 2020-06-18
HRP20231233T1 (hr) 2024-01-19
MD3395820T2 (ro) 2019-10-31
ES2944344T3 (es) 2023-06-20
SI4047002T1 (sl) 2023-07-31
LT4047002T (lt) 2023-05-10
CY1121885T1 (el) 2020-10-14
HK1255938B (zh) 2020-04-29
TN2019000210A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MA44021B1 (fr) Composés antitumoraux
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA39189A1 (fr) Dérivés de 1h-indazole et de 1h-indole antibactériens
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA46337B1 (fr) Composé de pyridine
MA44820B1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA40221A (fr) Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale
FR3066761B1 (fr) Nouveaux composes inhibiteurs des canaux ioniques
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA39305A3 (fr) Dérivés d'éthynyle
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
FR3020809B1 (fr) Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique
MA48455B1 (fr) Composés antitumoraux
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA39529B1 (fr) Agent stabilisant hautement efficace
MA20150280A2 (fr) Dérivés d'aryléthynyle
EA201891987A1 (ru) Производное 5-метил-6-фенил-4,5-дигидро-2h-пиридазин-3-она
FR3062796B1 (fr) Utilisation d'un compose appartenant a la famillle des diuretiques pour traiter le cancer